Trials / Completed
CompletedNCT05831644
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
A Randomized, Double-blind, Placebo-controlled, 2-way Cross-over Trial Evaluating the Effect of C21 on Endothelial Dysfunction and Safety in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Vicore Pharma AB · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C21 | C21 is an angiotensin II type 2 receptor agonist (ATRAG) |
Timeline
- Start date
- 2023-03-31
- Primary completion
- 2023-06-16
- Completion
- 2023-06-20
- First posted
- 2023-04-26
- Last updated
- 2024-11-12
- Results posted
- 2024-11-12
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05831644. Inclusion in this directory is not an endorsement.